NORDIC PHARMACEUTICALS ApS: Financial statements 2015
CVR: 27430015
Source: annual report 2015, Danish Business Authority
01/01/2015 – 31/12/2015
NORDIC PHARMACEUTICALS ApS (CVR 27430015) has filed annual accounts for 2015. In 2015, the company reported a gross profit of DKK 1,295,706 and a net result of DKK 281,651 compared with DKK 151,604 the year before. That is an increase of 44.2% compared with the year before. Equity in the 2015 report amounted to DKK 1,043,880. The solvency ratio was 29.1%.
- Gross Profit
- DKK 1,295,706
- Profit/Loss
- DKK 281,651
- Equity
- DKK 1,043,880
- Total Assets
- DKK 3,591,242
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2015 | - | 1.3 mio. | 282 t. | 1 mio. | - |
| 2014 | - | 899 t. | 152 t. | 762 t. | - |
| 2013 | - | 808 t. | 190 t. | 611 t. | - |
| 2012 | - | 959 t. | 421 t. | 614 t. | - |
Official annual report
How creditworthy is NORDIC PHARMACEUTICALS ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2015
As of November 17, 2015, Lars Bo Holløse Nielsen is registered as an owner of NORDIC PHARMACEUTICALS ApS with an ownership share of 50%.
As of November 17, 2015, Kea Ok Junge is registered as an owner of NORDIC PHARMACEUTICALS ApS with an ownership share of 50%.
NORDIC PHARMACEUTICALS ApS has published its annual report for 2014. Gross profit came to DKK 898,701, and the net result was DKK 151,604.
About NORDIC PHARMACEUTICALS ApS
NORDIC PHARMACEUTICALS ApS is a Danish company of the type Anpartsselskab based in Hvidovre, founded in 2003. The company is registered under the industry Fremstilling af andre fødevarer i.a.n.. The management consists of Lars Bo Holløse Nielsen. The board consists of Knud Benny Junge (chair). The company is owned by Lars Bo Holløse Nielsen and Kea Ok Junge. The company has 1 employee (2026). In 2025, the company reported a gross profit of DKK -165,886 and a net result of DKK -573,072 compared with DKK -2,664,416 the year before. Equity in the 2025 report amounted to DKK -1,725,613.